Thu. 9 May 2024, 4:10pm ET
Benzinga
Earnings, Earnings Beats, Earnings Misses, News
Revance Therapeutics (NASDAQ:RVNC) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.63) by 14.29 percent. The company reported quarterly sales of $51.936 million which missed the analyst consensus estimate of $56.634 million by 8.29 percent.